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ABSTRACT
Acute graft-versus-host disease, a major obstacle to the overall success of allogeneic hematopoietic stem cell
transplantation, is primarily induced by a subset of donor T cells. Most strategies to prevent acute graft-
versus-host disease target all T cells regardless of their specificity, and this leads to prolonged posttransplan-
tation immunodeficiency. Selective depletion of alloreactive T cells could spare protective immunity and
facilitate engraftment and graft-versus-leukemia effects. Recently described depletion strategies target acti-
vation markers such as CD25 that are expressed by alloreactive T cells. However, incomplete depletion may
occur when a single surface epitope or pathway of apoptosis is targeted that may not be fully and concurrently
expressed among all alloreactive cells. We now report on a novel strategy effective in both cord blood and
peripheral blood stem cell alloreactive T cells that simultaneously induces 2 independent pathways of apoptosis
after stimulation by recipient dendritic cells or Epstein-Barr virus–transformed B cells. First, we demonstrate
that the folate antagonist trimetrexate selectively depletes proliferating alloreactive precursors in vitro in a
dose- and time-dependent manner. Similarly, a second agent, denileukin diftitox, kills activated alloreactive T
cells expressing CD25. Most importantly, these 2 agents can exert their effects in concert with superior efficacy
while sparing resting bystander T cells, which remain available to mount antimicrobial or third-party re-
sponses.
© 2004 American Society for Blood and Marrow Transplantation
KEY WORDS
Acute graft-versus-host disease ● Allogeneic hematopoietic stem cell transplantation ●
Alloreactive T cells ● Trimetrexate ● Denileukin diftitox
m
c
l
i
r
a
(
a
c
t
uNTRODUCTION
Alloreactive T-cell subsets present within the di-
erse T-cell receptor (TCR) repertoire of allogeneic
ematopoietic stem cell grafts can recognize host tis-
ues in the context of HLA molecules and are critical
n the pathogenesis of acute graft-versus-host disease
aGVHD) [1,2]. Proinﬂammatory T-helper type 1
ytokines such as tumor necrosis factor (TNF)–,
nterleukin (IL)–1, interferon-, and some T-helper
ype 2 cytokines (such as IL-5 and IL-13) produced by
cells contribute to the development of aGVHD
ndependently and also in concert with direct cell- c
72ediated cytotoxicity exerted by the alloreactive T
ells themselves or by other recruited inﬂammatory
eukocytes [3-9]. The development of aGVHD is crit-
cally dependent on the initial reaction between allo-
eactive donor T cells and host antigens displayed on
ntigen-presenting cells (APCs) such as dendritic cells
DC) [10]. Host APCs will induce the expansion of
lloreactive clones identiﬁable by their unique TCR-
hain sequence [1]. Alloreactive T cells are also iden-
iﬁable in vitro in a mixed lymphocyte reaction (MLR)
pon activation by APCs as activated T cells enter the
ell cycle, and during blastogenesis they upregulate
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IL-2 IT and TMT Deplete Alloreactivity in Synergy
Bhe expression of IL-2 receptor (IL-2R) (CD25) [11],
long with other molecules of activation such as
LA-DR [12], OX40 [13,14], and CD69 [15].
Most clinical approaches currently used to prevent
r treat GVHD nonspeciﬁcally target the entire TCR
epertoire and even other leukocytes either by phar-
acologic suppression or by eliminating most T cells
n the basis of physical or immunophenotypic char-
cteristics, regardless of the speciﬁcity of their TCR
16]. These approaches contribute to profound post-
ransplantation immunodeﬁciency, delaying immune
ecovery and resulting in fewer graft-versus-leukemia
GVL) effects and an increased incidence of opportu-
istic infections.
To reduce posttransplantation immunodeﬁciency,
peciﬁc depletion of alloreactive T cells is currently
eing explored in the bone marrow transplantation
etting as a new approach to preserve the third-party
CR repertoire while reducing the incidence or se-
erity of GVHD. Most studies have targeted alloreac-
ive T-cell subsets via their upregulated expression of
he IL-2R chain surface molecules (CD25). The va-
idity of this concept has been demonstrated in rodent
odels and lately in humans as well [17-24]. Cell-
urface molecules other than CD25 may also be suit-
ble targets for antibody-based allodepletion [25-27] if
referentially expressed on the alloreactive subset.
here are other pathways to induce apoptosis in hu-
an alloreactive T cells, such as exploiting the re-
uced expression of an ion channel transporter on
ctivated alloreactive T cells [28]. However, regardless
f the target and pathway of apoptosis exploited, in-
omplete depletion may occur when the allodepletion
trategy targets a single surface epitope that may not
ave full expression at a given time point among all
lloreactive cells. Such “escape” of alloreactive T cells
ay also occur if T cells are stimulated with subopti-
al APCs, such as bulk mononuclear cells.
In an effort to enhance the sensitivity and efﬁcacy
f ex vivo allodepletion, we optimized methods of
llostimulation by using host-derived APCs and by
eveloping a novel approach of allodepletion. We
ypothesized that optimal depletion of alloreactive T
ell precursors may occur only when they are targeted
ia more than one of their unique cellular character-
stics acquired de novo after maximal stimulation. On
he basis of the clinical success of in vivo–administered
ethotrexate (MTX) in reducing the incidence and
everity of aGVHD [1,2], we tested (in vitro) an an-
iproliferative agent (trimetrexate; TMT) along with
n immunotoxin (IT) targeting the key activation
olecule CD25. We demonstrate that the combina-
ion of these 2 exclusive and individually effective
ethods is superior to either agent alone in the re-
oval of alloreactive T cells and that it preserves
hird-party T-cell reactivity. The host-reactive T-cell
ool undergoes apoptosis when proliferating alloreac- r
B&MTive T cells are exposed to the antifolate drug TMT in
ombination with an IL-2 chimeric IT. Their future
linical potential in ex vivo graft engineering is real-
stic because both tested agents are commercially
vailable as drugs with Food and Drug Administration
FDA)–approved indications in oncology and infec-
ious diseases. We also present experimental data to
emonstrate that the cooperation between these 2
gents is active in both peripheral blood stem cell
PBSC) and umbilical cord blood (UCB) grafts, com-
on cellular sources of HLA-mismatched allogeneic
tem cell transplants.
ATERIALS AND METHODS
pecimen Collection
Heparinized samples of fresh peripheral blood for
PC preparation and 1% to 2% of the allograft (ap-
roximately 1-2  107 total cells for cord blood and
-2  108 for PBSC) for the responder lymphocyte
reparation were obtained from patients undergoing
llogeneic stem cell transplantation from HLA-mis-
atched donors after written informed consent (ap-
roved by the Duke Hospital Institutional Review
oard) was obtained. Recipient heparinized blood 10
o 30 mL was also obtained before the initiation of the
reparative regimen to generate host monocyte-de-
ived DCs (MO/DCs). For children weighing less
han 10 kg, the blood draw did not exceed 3 mL/kg.
ccording to the protocol guidelines, a sample from
he graft was obtained to generate responder lympho-
ytes; however, in cases of UCB grafts, this sample was
btained only if it did not decrease the graft dose to
3  107 cells per kilogram after thawing. When
lloreactivity was studied in unrelated HLA-mis-
atched pairs with healthy volunteer donors, in-
ormed consent was obtained from healthy laboratory
olunteers before “responder” lymphocytes were pre-
ared. Epstein-Barr virus (EBV)–transformed lym-
hoblastoid cell lines (EBV/LCL) as APCs were used
rom the repository of the Pediatric Stem Cell Labo-
atory generated from anonymous donors. UCB sam-
les to generate responder T lymphocytes were ob-
ained from discarded specimens that were collected
nd processed by the Carolinas Cord Blood Bank at
uke University.
ntigen-Presenting Cells
Peripheral blood MO/DCs from transplant recipi-
nts or volunteer donors were prepared from the inter-
ace after Ficoll density centrifugation according to a
lightly modiﬁed previously published method [29].
rieﬂy, plastic adherent monocytes were cultured in
-well tissue culture plates (Falcon; BD Biosciences, San
ose, CA) in lymphocyte growth medium (LGM)-3 se-
um-free media (Clonetics, East Rutherford, NJ) supple-
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7ented with 1% autologous plasma, 800 IU/mL gran-
locyte-macrophage colony-stimulating factor (Amgen,
housand Oaks, CA), and 1000 IU/mL IL-4 (R&D,
inneapolis, MN) for 5 to 6 days. DC maturation was
nduced by adding TNF- 10 ng/mL (R&D) and pros-
aglandin E2 0.01 mmol/L (Sigma, St. Louis, MO) [29]
n the last day of culture. To verify sufﬁcient maturation
f DCs, they were monitored by 3-color ﬂuorescence-
ctivated cell sorting (FACS) for the expression of sur-
ace CD80, CD86, and CD83 (all phycoerythrin conju-
ated) and HLA-DR-peridinin chlorophyll protein
PerCP) while staining negative for ﬂuorescein iso-
hiocyanate (FITC)–conjugated lineage cocktail (CD3,
D14, CD19, and CD20). The ﬁnal product was ap-
roximately 60%pure by these criteria. The entire prod-
ct was -irradiated before use as stimulators of allo-
eactive lymphocytes. EBV/LCL was produced from
eripheral blood mononuclear cells by standard pub-
ished methods [30].
LR and Selective Depletion of Alloreactivity
Host APCs (DC or EBV/LCL) were washed free of
ytokines and were irradiated at the Duke University
edical Center Blood Bank with cesium 137, 1500 rad
or DC and 7500 rad for EBV/LCL, before exposure to
esponder T cells. Responder lymphocytes were Ficoll
ensity gradient interface cells depleted of adherent
onocytes over human immunoglobulin G–coated
lastic (Gammaimune; Bayer Healthcare, Berkley, CA).
n experiments in which sufﬁciently high numbers of
esponder cells were available, further immunomagnetic
nrichment of T cells was achieved with Dynabeads
Dynal, Oslo, Norway) or magnetically activated cell
orting (Miltenyi Biotec, Auburn, CA) to deplete
D19 B cells and CD56 NK cells. The ﬁnal re-
ponder cell concentration was maintained at 1 to 1.5
06/mL in LGM-3 media supplemented with 1% recip-
ent plasma. Cocultures were performed in round-bot-
omed 96-microwell tissue culture plates for EBV/LCL
timulators, and ﬂat-bottomed plates were used when
O/DCs served as APCs (Falcon) with 1 to 1.5  105
esponder cells per 0.1 to 0.15mL per well at stimulator-
esponder ratios of 1:10. In parallel to the microwells,
dditional macrowells were set up (12- to 48-well plates,
-2 mL per well, at APC-responder cell ratios of 1:10-
:20) to generate responder lymphocytes for the re-
timulation experiments (secondary MLRs).
TMT, a nonclassic folate antagonist (Neutrexin;
arner Lambert, Ann Arbor, MI), was added at the
nitiation of APC and responder cell coculture for the
ndicated length of time. Recombinant IL-2 conju-
ated with diphtheria IT (IL-2 IT; denileukin diftitox,
ntak; Ligand Pharmaceutical, Inc., San Diego, CA),
chimeric protein that is cytotoxic against cells ex-
ressing IL-2R (CD25), in association with IL-2R
nd  chains, was added directly into the media of the c
74rimary MLR at indicated time points at 0.5 to 1.5
g/mL concentrations, as indicated. After 30 minutes
f incubation at 37°C, the IL-2 IT was washed out
ith fresh LGM-3 media. All experiments were per-
ormed from thawed aliquots that were frozen at
20°C of a single lot of TMT and 2 different lots of
L-2 IT. Unmanipulated control wells were treated
ith media alone and were handled in identical ways
mock-treated), representing the control with maxi-
al alloactivation but without depletion intervention.
n the ﬁfth day of the primary MLR, cells from the
MT-treated, IL-2 IT–treated, and mock-treated
acrowells were harvested, washed, counted, and re-
ultured in secondary MLR, with fresh APCs as indi-
ated at a stimulator-responder ratio of 1:10. Primary
LRs set up in 96-well microwells in duplicate or
riplicate were analyzed in proliferation and ﬂow cy-
ometric assays as described below. To demonstrate
fﬁcient depletion of alloreactivity, secondary MLR
lates were set up in 96-microwell tissue culture plates
Falcon) with fresh APCs (MO/DCs or EBV/LCLs)
dentical to the ones stimulating the primary MLR.
esponder lymphocytes were harvested from the mac-
owells that were treated as indicated, with or without
MT or IL-2 IT. To test the preservation of the
CR repertoire toward third-party stimulation, plas-
ic adherent monocytes autologous with the responder
ymphocytes were used as APCs in replicates for stim-
lation with 10 g/mL candida antigen (Greer Lab-
ratories Inc., Lenoir, NC) or 5 g/mL phytohemag-
lutinin (PHA; Difco Laboratories, Detroit, MI),
hereas anti–third-party alloreactivity was tested with
-irradiated allogeneic EBV/LCL.
onitoring the Sensitivity and Selectivity of
llodepletion
Proliferation assays. On the ﬁfth day of the primary
LR or third to ﬁfth day of secondary MLR (day
-10 since the graft was obtained), the experimental
nd control wells in the 96-well plates were pulsed
ith 1 Ci per well of 3H-thymidine (3HTdR; New
ngland Nuclear, Boston, MA) and incubated at 37°C
or 8 to 12 hours, as described previously [31]. Results
re expressed graphically as the mean counts per
inute of triplicates/duplicates 	 SD. Control wells
ontaining unstimulated T cells or irradiated APCs
lone were incorporated at 1000 counts per minute.
Flow cytometry to monitor activation, proliferation,
ytokine secretion, and apoptosis. Harvested cells were
tained with a commercial 4-color reagent, Multitest
Becton Dickinson, San Jose, CA), to determine the
D3 T-cell content within the lymphocyte gate. To
onitor surface markers of activation on T cells, the
L-1 and FL-2 channels were used for the ﬂuoro-
hrome-conjugated antibodies of interest (CD25,
D69, OX40, and HLA-DR), whereas ﬂuorescent
hannel (FL)-3 was dedicated to gate on CD3-PerCP/
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IL-2 IT and TMT Deplete Alloreactivity in Synergy
By5 T cells. The CD4 or CD8 T-cell subsets
ere identiﬁed in the FL-4 channel as direct conju-
ates of allophycocyanin. All ﬂuorochrome-conju-
ated monoclonal antibodies and reagents were pur-
hased from BD Biosciences. For intracellular (IC)
taining, antibodies of interest and matching isotype
ontrols were added at room temperature to ﬁxed and
ermeabilized cells after surface staining with anti-
D3 and anti-CD4 antibodies. The cells were ﬁxed
ith FACS Lyse buffer and permeabilized (FACS
erm Solution) before incubation with IC antibodies
or 30 minutes at room temperature, after which the
ells were washed again and resuspended in FACS
yse buffer until acquisition. IC FACS staining with
i-67/FITC identiﬁes proliferating cells, whereas IC
taining to detect active caspase-3/phycoerythrin
dentiﬁes cells undergoing apoptosis. IC granzyme
/FITC staining was used to monitor T cells with
ytotoxic potential. For determining IC TNF- pro-
uction by alloreactive T cells, the secretion inhibitor
refeldin A was added to the MLR media at 10 g/mL
to 12 hours before cells were harvested. Fluorescent
ellular events were acquired on a dual laser (488 and
35 nm; FACSCalibur [BD]) and analyzed with
ellQuest software (BD).
tatistics
3HTdR incorporation by proliferating cells in rep-
icates was expressed graphically as the mean 	 SD.
easuring the effect of TMT time exposure on the
nhibition of proliferation was calculated by express-
ng (in percentages) the mean 	 SD reduction of
roliferation when TMT was kept in the media for an
dditional day. For example, to compare 3 versus 4
ays of TMT exposure, the following formula was
sed
MLR of 3 days with TMT
 MLR of 4 days with TMT ⁄
MLR of 3 days with TMT ⁄ 100
paired 2-tailed Student t test (Microsoft Excel; Mi-
rosoft, Redmond, WA) was used to determine statis-
ical signiﬁcance between samples that evaluated dif-
erent depletion methods.
ESULTS
MT Depletes Alloreactive Cells in a Dose-
ependent Manner by Reducing Proliferation and
nducing Apoptosis
Potent activation of host-reactive T cells is essential
o critically evaluate alloreactive T cell–depletion strat-
gies, best achieved by “professional” APCs. Allogeneic
O/DCs or EBV/LCLs presenting mismatched major
LA antigens in a primaryMLR fulﬁll this criterion and c
B&MTnduce a robust proliferative response in the alloreactive
-lymphocyte subset. By the ﬁfth day of stimulation,
lose to 50% of all T cells may enter the cell cycle and
xpress Ki-67, a nuclear cell proliferation antigen
Figure 1A), as the alloreactive precursors dramatically
xpand. During and even preceding T-cell blastogenesis,
everal activation markers (including CD25) are ex-
ressed over time. We tested the effect of a nonclassic
olate antagonist (TMT) on T-cell proliferation in vitro.
his lipophilic antifolate, unlike the classic antifolate
TX, is nonpolyglutamated and can enter cells via a
arrier-independent pathway. This renders it a more
otent suppressor of DNA synthesis and cellular prolif-
ration than MTX [32]. In pilot experiments, we found
n inverse relationship between the concentration of
MT and the percentage of T cells entering the cell
ycle in PHA-driven T-cell proliferation (data not
hown). Similarly, when increased graded concentrations
f TMT (108 to 106 mol) were added to the medium
t the initiation of an alloreactive MLR, there was pro-
ressive reduction of proliferating T cells as monitored
y the IC/nuclear expression of Ki-67 (Figure 1B-D).
he dose-dependent inhibition of proliferation and
NA synthesis among alloreactive T cells was also de-
onstrable in parallel by the reduced uptake of 3HTdR
rom the MLR medium (Figure 1F). Whereas TMT
learly reduced alloreactive T-cell blastogenesis in a
ose-dependent manner, alloreactive T-cell precursors
ere undergoing apoptosis simultaneously in a similarly
raded and dose-dependent manner, as measured by the
rogressive increase in IC expression of active caspase-3
ith higher TMT concentrations (Figure 1B-D). The
trong stimulation afforded by MO/DCs or EBV/LCLs
riggered DNA synthesis in the alloreactive T-cell pool
nd eventually led to cell death in the TMT-loaded
edia. Despite the proapoptotic effect of TMT on the
lloreactive T-cell subset, most of the residual nonallo-
eactive T cells remained in the resting state and were
pared from any bystander toxicity, even at the highest
MT concentration tested (106 mol; Figure 1D).
hen we investigated whether the effects of TMTwere
ependent on the source of the graft, we found that
MT, by virtue of inducing apoptosis in proliferating
lloreactive precursors, induced depletion of activated
lloreactive T cells both from PBSC grafts and from
ord blood, as depicted in Figure 2A and B, respectively.
MT Depletes Alloreactive Cells in a
ime-Dependent Manner
We hypothesized that TMT’s effect as a folate an-
agonist on alloreactivity was dependent not only on its
oncentration in the media, but also on the duration of
ts exposure, as predicted from in vitro studies with
TX [32]. To test this, we compared the effects of 3
ersus 4 and 4 versus 5 days of TMT exposure in the
rimary MLR. Enhanced inhibition of alloreactive T-
ell proliferation as a result of prolonging TMT expo-
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7ure was evident with the passage of each additional day
s measured by the percentage reduction in alloreactive
-cell proliferation (Figure 3). Reduced alloreactive pro-
iferation was demonstrable when 4 days of TMT expo-
ure was compared with 3 days (by 29% 	 11%; n 
 6;

 .05) and when 5 days of exposure was compared
ith 4 days (by 15% 	 9%; n 
 5; P 
 .02).
L-2 IT Depletes Alloreactive Cells by Reducing
roliferation and Inducing Apoptosis
In preliminary experiments (data not shown) with
O/DCs or EBV/LCLs as APCs, we established that
urface CD25 upregulation was time dependent. Over
ime, an increasing percentage of the stimulated T cells
n a primary allogeneic MLR upregulate CD25 expres-
ion and may exceed 50% of all T cells by the ﬁfth day.
his phenomenon was observed regardless of whether
CB or adult peripheral blood T cells were stimulated.
igure 1. Trimetrexate (TMT) depletes alloreactivity in a dose-de
I-67) or apoptosis (cells expressing IC active caspase-3) among a
riginal APCs (EBV/LCLs) on day 5 of the secondary MLR. A, Unm
timulation by EBV/LCLs. B-D, Proliferating alloreactive T cel
ose-dependent manner with an increased molar TMT concentrati
f apoptotic T cells expressing active caspase-3 IC (cells in red) wa
n CD3 T cells. E, IL-2 IT added on day 3 at 0.5 g/mL for 30 mi
imilar to TMT. F, Proliferation of alloreactive T cells was quanti
CPM). The responder cells were from the same MLRs as cells dehen we targeted alloreactive T cells expressing CD25 e
76ith a commercially available IL-2 IT in the primary
LR, we saw comparable antiproliferative and proapop-
otic effects as with high TMT concentrations (Figure
E and F; Figure 2A and B). Upon IL-2R–mediated
ntry into the cytosol, the diphtheria toxin A-fragment
f denileukin diftitox is cytotoxic and inhibits cellular
rotein synthesis by catalyzing adenosine diphosphate
ibosylation of elongation factor-2 [33,34]. However,
nlike with TMT treatment, alloreactive T-cell deple-
ion achieved by IL-2 IT was not time dependent when
he addition of IL-2 IT was tested on day 3, day 4, or day
of the primary MLR (data not shown).
MT and IL-2 IT Act in Synergy to Deplete
lloreactive T Cells
We sought to investigate the 2 methods tested pre-
iously for possible synergy in removing alloreactive T
ells. We hypothesized that combining the 2 methods,
t manner. A-E, FACS proﬁle of proliferation (cells expressing IC
ive peripheral blood T cells at the end of re-stimulation with the
ated alloreactive T cells were mock-treated while receiving maximal
essing Ki-67 (cells in green) were progressively depleted in a
ed to an MLR for the ﬁrst 3 days. Simultaneously, the percentage
sed similarly in a dose-dependent way. All depicted cells are gated
o a primary MLR induced antiproliferative and proapoptotic effects
y 3H-thymidine incorporation and expressed in counts per minute
in (A-E). Results are representative of 6 experiments.penden
lloreact
anipul
ls expr
on add
s increa
nutes t
tated bach capable of inducing apoptosis by nonoverlapping
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IL-2 IT and TMT Deplete Alloreactivity in Synergy
Bays, would enhance the efﬁcacy of depletion and reduce
he probability of escape among alloreactive T cells. The
ationale for the combination approach was supported
y ﬂow cytometric analysis of alloreactive T-cell activa-
ion at the end of the primary MLR when CD4 and
D8 T cells were monitored for the simultaneous
xpression of IC Ki-67 along with surface CD25. We
ound that 10% of proliferating (Ki-67) alloreactive
cells do not simultaneously express CD25, rendering
hese cells (Ki-67/CD25) potentially refractory to
L-2 IT (data not shown). Similarly, 20% of CD25-
xpressing cells may not proliferate, rendering these cells
CD25/Ki-67) potentially refractory to TMT (data
ot shown). Indeed, each time the 2 agents were com-
ined by using continuous exposure of TMT in the
edia and IL-2 IT as a 30-minute pulse on days 3 or 4,
e observed superior efﬁcacy in reducing alloreactive
-cell proliferation (Figure 2A-C) compared with either
ethod alone. The combination of TMT plus IL-2 IT
as the most effective experimental arm in all experi-
ents (n 
 12; P  .001), regardless of whether UCB
n
 4) or peripheral blood (n
 7) was the source of the
lloreactive T cells. The combination of TMT plus IL
T resulted in more than a log reduction (median, 21.4-
old; 	6.9; n 
 13) of alloreactive T-cell proliferation,
ith no signiﬁcant difference (P 
 .12) whether MO/
igure 2. Trimetrexate depletes alloreactivity in a time-dependent
ependence on continued exposure to TMT at 106 mol, demonstr
ersus 4 or 5 days). Proliferation of alloreactive T cells was quantit
CPM). Results are representative of 6 experiments.Cs (n 
 5) or EBV/LCLs (n 
 8) were used as s
B&MTtimulators. To simulate the kinetics of the continuous
-cell activation that presumably occurs in vivo in pa-
ients who receive allogeneic stem cell transplants and
lso to verify the efﬁcacy of alloreactive T-cell depletion,
cells that were harvested at the end of the primary
LR were rechallenged ex vivo with the original APCs.
he responders harvested from the macrowells on day 5
f the primary MLR were washed, counted, and re-
xposed to fresh irradiated aliquots of APC in secondary
LRs in the absence of any further manipulation. Upon
e-stimulation in the secondary MLR, the combination
f TMT plus IL-2 IT remained the most effective arm
f allodepletion in 6 of 7 experiments (P 
 .02; Fig-
re 2C).
Once we established that the combined use of
MT and IL-2 IT is synergistic in removing prolif-
rating alloreactive T-cell precursors from both pe-
ipheral blood and cord blood HLA-mismatched al-
ografts, we evaluated other effects of this synergy on
he responding T-cell pool. We tested for TNF-
ecretion elicited by host APCs (Figure 4), an impor-
ant soluble mediator and ampliﬁer of GVHD, and in
arallel for the relative size of the T-cell pool express-
ng granzymes A and B and perforin, members of the
ranule exocytosis pathway considered to be crucial
or cell-mediated cytotoxicity [8]. Although in the
r. The efﬁciency of alloreactive T-cell depletion was tested for its
creasing efﬁcacy with each additional day passing (3 days’ exposure
3H-thymidine incorporation and expressed in counts per minutemanne
ating in
ated byecondary MLR that had been repeatedly stimulated
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7here was a marked expansion of activated TNF-–
nd granzyme A–secreting CD4 and CD8 alloreac-
ive T cells in the fully alloactivated condition (“un-
anipulated” in Figures 1-6), the TMT plus IL-2 IT
reatment deleted the alloreactive subset, leaving be-
ind a spared viable T-cell population that expressed
aseline levels of TNF- and granzyme A (Figures
igure 3. TMT and IL-2 IT act synergistically in depleting PBSC
r UCB alloreactive T cells. A, The effect of allodepletion methods
n alloreactive T-cell proliferation was evaluated at the end of the
rimary MLR on the ﬁfth day by measuring 3H-thymidine incor-
oration (counts per minute). Responder lymphocytes were gener-
ted from PBSC grafts and were stimulated by HLA-mismatched
BV/LCLs. TMT exposure was 3, 4, or 5 days during the MLR, as
epicted, and IL-2 IT was administered on the fourth day of
rimary MLR for 30 minutes and was then washed out. Results are
epresentative of 6 experiments. B, Cord blood alloreactive T cells
timulated by allogeneic MO/DCs were depleted by TMT plus
L-2 IT in a synergistic way. TMT exposure was for 5 days; IL-2 IT
as administered on the fourth day of primary MLR. Results are
epresentative of 5 experiments. C, Effect of allodepletion methods
n alloreactive T-cell proliferation as evaluated at the end of re-
timulation (third day of secondary MLR; eighth day from obtain-
ng the graft sample). PBSC responder lymphocytes from the pri-
ary MLR presented in Figure 3A were washed and then re-
timulated with original EBV/LCLs in a secondary MLR. Results
re representative of 6 experiments.
igure 4. TMT and IL-2 IT deplete TNF-–secreting alloreactive
rimary MLR. Responder lymphocytes isolated from PBSCs were st
nd were manipulated as indicated except the unstimulated control.
fforts.) B, Percentage of T cells that expressed IC TNF- in each
esults are representative of 4 experiments.
78A, 4B, and 5, respectively), similar to the phenotype
f unstimulated resting T cells.
verall T-Cell Responsiveness and Third-Party
esponses Are Preserved after Depletion of
lloreactive T Cells
The preeminent task with demonstrating selec-
ive depletion of alloreactive T cells is to ascertain
hether overall T-cell responsiveness, including
on–host-reactive third-party responses, is pre-
erved among T cells that survived the exposure to
MT and IL-2 IT in the primary MLR. To address
his functional question, residual T cells were
ashed off the depletion agents after completion of
he primary MLR and were subsequently exposed to
arious T-cell mitogens. They were compared in
arallel with control T cells that had not been
xposed to T cell–depletion agents. Nonspeciﬁc
olyclonal mitogen stimulation by PHA demon-
trated not only preserved viability, but also com-
arable proliferative capacity of the viable T cells
fter TMT plus IL-2 IT exposure with unmanipu-
ated controls (Figure 6A). Similarly, preservation
f functional T-cell subsets with distinct TCR spec-
ﬁcity was demonstrated by measuring anti–third-
arty allogeneic responses (Figure 6B) and micro-
ial antigen-speciﬁc responses induced by candida
ntigen–loaded autologous MO/DCs (Figure 6C).
ISCUSSION
In this report we describe the feasibility and efﬁ-
acy of a novel in vitro procedure combining TMT
ith IL-2 IT to selectively remove alloreactive T cells
rom major histoincompatibility complex (MHC)–
ismatched allografts in serum-depleted milieu. To
ncrease the sensitivity of identifying alloreactive T-
s. A, Percentage of T cells expressing IC TNF- at the end of the
d for 5 days by MO/DC stimulators in the primary MLR for 5 days
anipulated” indicates full alloreactive activation without depletion
after re-stimulation with fresh MO/DCs in the secondary MLR.T cell
imulate
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Bell precursors, we used professional APCs as the most
otent activators of alloreactivity. By using recipient
O/DCs or EBV/LCLs, we triggered vigorous allo-
eactivity in a primary MLR that, when further am-
liﬁed by re-stimulation with fresh host-derived APCs
n a secondary MLR, led to the vigorous proliferation
Ki-67 expression and 3HTdR uptake) and expansion
f activated TNF-– and granzyme A–secreting
D4 and CD8 alloreactive T cells. Although de-
eting this alloreactive population possessing a highly
ctivated and cytotoxic immunophenotype, the tested
llodepletion methods spared the residual surviving T
ells in an unstimulated resting stage expressing near-
asal levels of TNF- and granzyme A.
Cavazzana-Calvo et al. [17,18] demonstrated in
ioneering work initially in mice that anti–IL-2R–
peciﬁc IT inhibited both MLR in vitro and HLA-
estricted T-cell cytotoxicity in the haplotype-mis-
atched setting. The T-cell depletion was host
peciﬁc, because the third-party response was rela-
ively unaffected and the T-cell reactivity against in-
ectious agents was preserved [35]. An in vivo mouse
odel demonstrated attenuation of GVHD after
ransplantation with grafts depleted of allospeciﬁc T
ells [18]. The ﬁrst human preclinical model that used
nti-CD25 (anti–IL-2R) IT in vitro, in human hap-
otype-mismatched related individuals, demonstrated
p to 90% depletion of alloreactivity, whereas 64% of
hird-party reactivity was preserved [19]. Notably, the
rowth of normal bone marrow colony-forming unit–
ranulocyte-macrophage was not signiﬁcantly affected
y the IT. Since the initial study, the feasibility of
lloreactive T-cell depletion without loss of antiviral
r GVL responses by the anti-CD25–linked IT has
een conﬁrmed in further detail [20,21,23,24].
Although several of the previously described de-
letion studies used bulk recipient mononuclear cells
igure 5. TMT and IL-2 IT deplete alloreactive CD8 T cells that
xpress granzyme A. Responder lymphocytes isolated from PBSCs
ere stimulated for 5 days by MO/DCs in a primary MLR, after
hich each group was re-stimulated with the same APCs in the
econdary MLR (except the unstimulated control that had no APC
resent). The percentage of CD8APC T cells that expressed
ntracellular granzyme A/FITC after re-stimulation is presented.
esults are representative of 4 experiments.s stimulators of alloreactivity, it is only recently be- 3
B&MToming accepted that professional APCs are the key
nitiators of alloreactivity [6,36]. The development of
GVHD in vivo requires host APCs such as skin
angerhans cells, a member of the DC system, to
rigger the activation, expansion, and cytokine pro-
uction of alloreactive lymphocytes, which will lead to
he recruitment of additional host and donor cells to
ontribute to the cytokine storm that is a hallmark of
he effector phase of aGVHD [4,5,36]. DCs are al-
ost 2 log more powerful stimulators of alloreactivity
hen compared with bulk peripheral blood mononu-
lear cells [37,38]. DCs not only express MHC prod-
igure 6. TMT and IL-2 IT deplete alloreactive T cells but
reserve overall T-cell responsiveness and third-party reactivity.
eripheral blood T cells were stimulated by irradiated EBV/LCLs
nd were treated with either TMT or IL-2 IT. Unmanipulated cells
ere rested without any alloactivation or treatment with depleting
gents. On day 5, cells were washed and were re-stimulated with
utologous monocytes and loaded with 5 g/mL of PHA (A) for 3
ays or 10 g/mL of candida antigen (C) for 5 days before pulsing
ith 3H-thymidine. Proliferation is expressed in counts per minute
CPM). Third-party responsiveness (B) was tested in an allogeneic
LR. On day 5 at the end of the primary MLR stimulated by
O/DC responder cord blood, cells were washed off the deletion
gents indicated and were re-stimulated with irradiated third-party
BV/LCLs for another 5 days before the cultures were pulsed with
H-thymidine. Proliferation is expressed in CPM.
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7cts at the highest density, but also retain bound
eptides, also called minor histoincompatibility antigens,
onger than other APCs [39]. These features that
rovide sustained and robust TCR signaling are
aired in mature DCs with the most abundant acces-
ory signaling capacity via the intercellular adhesion
olecules, the B7 family [40], 4-1BBL, CD40 [41],
X40L [42], and secreted cytokines such as IL-12
43,44]. In certain clinical scenarios, the generation of
ecipient MO/DCs may not be feasible or desired,
uch as for patients with myeloid malignancies. For
hese potential candidates of alloreactive T cell–de-
leted grafts, to preserve myeloid lineage-speciﬁc T-
ell clones that could exert a beneﬁcial GVL effect, we
how that EBV/LCLs are equally potent activators of
lloreactivity. As shown previously, they present HLA
ntigens and co-stimulatory molecules at very high
xpression levels, rendering them highly immuno-
enic [24,45,46].
In this study, we ﬁrst demonstrated the ex vivo
fﬁcacy of TMT, a potent lipophilic synthetic MTX
nalog that induces apoptosis when host-reactive T
ells enter the cell cycle, and then we identiﬁed the
ptimal conditions for TMT to remove alloreactive T
ells. TMT is a competitive inhibitor of dihydrofolate
eductase, a vital enzyme for purine and thymidine
ynthesis and cell replication. TMT is an excellent
andidate for ex vivo graft engineering because it is a
onclassic folate antagonist; unlike MTX, enters cells
ia a non–energy-dependent pathway; and is not poly-
lutamated. TMT was approved by the FDA as an
rphan drug for the treatment of Pneumocystis carinii
neumonia in patients with acquired immunodeﬁ-
iency syndrome and is also active against other par-
sitic infections, such as malaria and toxoplasmosis.
dditionally, in vivo–administered TMT has been
valuated in a phase I clinical trial along with cyclo-
porin A as GVHD prophylaxis in the HLA-mis-
atched related donor transplant setting and was
ound to be similar in efﬁcacy to MTX [47].
Comparable in vitro depletion efﬁcacy with TMT
as achieved by a commercially available IT that targets
ctivated T cells that upregulate the surface expression of
he IL-2R. This chimeric molecule is signiﬁcantly dif-
erent from the CD25 ITs that have been previously
valuated in vitro by several groups [20,21,23,24]. De-
ileukin diftitox is a receptor-targeted cytotoxic fusion
rotein generated in an Escherichia coli expression system
omposed of the recombinant chimeric molecule of IL-2
nd diphtheria toxin. It is cytotoxic against cells express-
ng IL-2R (CD25) in association with IL-2R and 
hains. It has been FDA approved for cutaneous T-cell
ymphoma, a malignancy that is characterized by the
onstitutive expression of CD25 on activated T cells
nﬁltrating the skin.Most recently, it has been also found
o be effective as front-line treatment for steroid-refrac-
ory aGVHD [48]. Thus, both TMT (Neutrexin) and m
80L-2 IT (Ontak) have been FDA approved for in vivo use
ndividually for infectious or malignant conditions. This
enders them eminently suitable for ex vivo graft engi-
eering.
The key ﬁnding of our studies is the demonstra-
ion of the principle, in already preclinical serum-free
onditions, that when these individually effective
gents are combined, superior efﬁcacy of ex vivo allo-
eactive T cells can be achieved after the potent acti-
ation by 2 interchangeably used host APCs. We also
emonstrated that for TMT, the efﬁcacy of depletion
as both time and concentration dependent. Several
reviously published methods have used 2 to 3 days of
ctivation with bulk peripheral blood mononuclear
ells serving as surrogate APCs, thus achieving poten-
ially suboptimal activation of some alloreactive T-cell
recursors. In contrast, our most effective condition
sed 5 days of TMT exposure of a 5-day MLR stim-
lated by professional APCs with IL-2 IT treatment
dded on either day 3 or 4. We postulate that for some
lloreactive T cells with relatively lower afﬁnity, ex-
ended activation may be necessary to generate the
ctivated phenotype that can be the subject for selec-
ive targeting. In this study, the selective allodepletion
as performed in a primary MLR; however, the true
fﬁcacy of allodepletion was best demonstrated in re-
timulation experiments (secondary MLR) that mimic
he continued activation state of alloreactivity occur-
ing in vivo in the immediate postgrafting period.
In this feasibility study we also demonstrated that
he cooperation exerted by TMT and IL-2 IT is
ffective regardless of whether T cells are from PBSC
r from UCB grafts, thus opening the ﬁeld for graft
ngineering in both clinical scenarios. UCB and
BSC are the most commonly used stem cell sources
or HLA-mismatched transplantation, and allode-
leted aliquots could be used for various adoptive
-cell strategies. Aliquots of cord blood or PBSC
rafts devoid of alloreactive potential could be an ideal
tarting population for ex vivo expansion and adoptive
ransfer as donor leukocyte infusions (DLI) to reduce
osttransplantation opportunistic infections that arise
n the T-cell lymphopenic period. If DLI could be
afely administered relatively early after transplanta-
ion, this could also aid engraftment and skew toward
ull donor chimerism in T cell–depleted HLA-mis-
atched haploidentical stem cell grafts. Despite the
nherent immaturity of naive UCB T cells [49], selec-
ively allodepleted UCB could be an ideal starting
opulation for in vitro priming strategies aimed at
enerating virus-speciﬁc cytotoxic T lymphocytes for
ubsequent DLI and adoptive immunotherapy [50].
We also propose that either fully mature host-de-
ived myeloid DCs or EBV/LCLs may be used as efﬁ-
ient APCs to present recipient HLA antigens to donor
cells. For lymphoid malignancies, the use of APCs of
yeloid origin—such as mature MO/DCs—might be
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Breferable, whereas in myeloid malignancies, EBV/
CLs would be optimal host-derived APCs. This selec-
ive approach would potentially spare GVL precursor
requency directed against hematopoietic lineage-spe-
iﬁc antigens [51,52]. Although the main focus of our
xperiments was to develop, critically evaluate, and char-
cterize the immunobiology of new and superior al-
odepletion methods, we can estimate the clinical feasi-
ility of this approach when DCs are used as host APCs.
rom approximately 10 mL of peripheral blood with
ormal counts, typically approximately 1  106 MO/
Cs can be generated. This is sufﬁcient to stimulate
pproximately 1  107 puriﬁed T cells in a primary
LR. Allodepletion with the combination method is
ssociated with several steps of manipulations/washes
ith approximately 30% recovery of the input T cells. If
third of these are set aside to verify the efﬁcacy of
llodepletion, approximately 2  106 CD3 T cells
ould be available for potential adoptive T-cell therapy.
f a dose-escalation trial were initiated with 1  105
llodepleted HLA-mismatched CD3 T cells per kilo-
ram, then 10 mL of peripheral blood lymphocytes
rawn from a patient weighing approximately 20 kg
ould provide sufﬁcient host MO/DCs for a single DLI
nfusion. Increasing the recipient blood draw and slightly
igher APC-responder ratios (such as 1:20 with highly
uriﬁed T-cell responders) could further increase the T
ells available for potentially higher dose levels. The
umeric limitations of obtaining host MO/DCs can be
ypassed when immortalized EBV/LCLs are used as
PCs. The key factor in deciding the source of host
PC if both are potentially available should be the type
f malignancy for leukemia patients. For recipients with
onmalignant conditions, primary MO/DCs are prefer-
ble, as opposed to virally immortalized LCLs, if sufﬁ-
ient numbers can be generated. However, it may be
rudent to generate EBV/LCLs on all patients to have
hose APCs available in case the yield or quality of
O/DC preparation is suboptimal.
The concern that anti-EBV reactivity would be
epleted along with the alloreactive pool when EBV/
CLs are used as APCs needs to be considered. How-
ver, when recipient-donor pairs are mismatched at
HC loci, the MHC-restricted minor histocompati-
ility antigen (EBV)–speciﬁc T-cell clones may
argely remain unperturbed in a primary MLR that is
riven by direct MHC allostimulation. Supporting
xperimental evidence was recently obtained by enu-
erating interferon-–secreting EBV-reacting T cells
n a haploidentical model in which EBV/LCLs were
sed as stimulators before use of an anti-CD25 IT
24]. However, cross-reacting epitopes have been de-
cribed between viral epitopes and alloantigens [53],
nd, consequently, depleting T cells with dual speci-
city could lead to some reduction of virus- or other
icrobe-speciﬁc T-cell precursor frequencies in both
BSC and marrow grafts. This is of lesser concern in
B&MThe context of unrelated UCB transplants because of
he lack of previous microbial exposure and priming of
aive UCB T cells.
Using an IL-2 IT may theoretically also lead to
emoval of regulatory CD25 T cells [54]. However,
D25 targeting in current organ transplantation prac-
ice has shown a clinically beneﬁcial reduction of al-
oreactivity that has reduced the rate and severity of
ejection. Similarly, it has been documented in hema-
opoietic transplantation that GVHD can be success-
ully treated by CD25 targeting [2].
In summary, these data are the ﬁrst, to our knowl-
dge, to demonstrate that the combined application of 2
ethods that target different cellular proﬁles of alloreac-
ivity provides enhanced efﬁcacy and preserves nonallo-
eactive T cells in a resting state. The combination
pproach may be needed as a safeguard to achieve clin-
cally relevant and safe allodepletion in cases in which
lloreactive T cells express low levels of CD25 (or other
urface markers of activation) or in cases in which there
s a relative lack of proliferation and DNA synthesis
mong alloreactive T cells. In case host antigens are
resented in a suboptimal way, either because of insuf-
cient numbers or low activation states of APCs, one
ould expect a heterogeneous activation pattern among
lloreactive precursors that would render them less likely
o be identiﬁable through a single activation marker or
iological characteristic. Incomplete removal of partially
ctivated alloreactive T cells by a given depletion
ethod could lead to the adoptive transfer of expanded
lloreactive T cells that would be present at an even
igher frequency than were originally in the graft, thus
riggering or exacerbating aGVHD. Experimental data
aution of the potential dangers of adoptive transfer of ex
ivo–activated allosensitized host-reactive T cells be-
ause they are less likely to respond to calcineurin inhib-
tors such as cyclosporin A once activated in vitro [55].
CKNOWLEDGMENTS
This work was supported by The National Mar-
ow Donor Program-Marrow Transplant Research
rant, The Lisa Stafford Memorial Research Prize
P.S.), and grant nos. 1PO1-HL-67314-01A1 (P.S.
nd J.K.) and N01-HB-67141 (J.K.). We are grateful
o Peter Cole and Reid Bissonette for helpful discus-
ions.
EFERENCES
1. Michalek J, Collins RH, Hill BJ, Brenchley JM, Douek DC.
Identiﬁcation and monitoring of graft-versus-host speciﬁc T-
cell clone in stem cell transplantation. Lancet. 2003;361:1183.
2. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host
disease: pathobiology and management. Exp Hematol. 2001;29:
259.3. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis
781
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
P. Szabolcs et al.
7factor/cachectin is an effector of skin and gut lesions of the
acute phase of graft-vs.-host disease. J Exp Med. 1987;166:1280.
4. Ferrara JL. The cytokine modulation of acute graft-versus-host
disease. Bone Marrow Transplant. 1998;21(suppl 3):S13.
5. Antin JH. Acute graft-versus-host disease: inﬂammation run
amok? J Clin Invest. 2001;107:1497.
6. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-
host disease does not require alloantigen expression on host
epithelium. Nat Med. 2002;8:575.
7. Deeg HJ. Cytokines in graft-versus-host disease and the graft-
versus-leukemia reaction. Int J Hematol. 2001;74:26.
8. Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host
disease. Blood Rev. 2003;17:187.
9. Jordan WJ, Brookes PA, Szydlo RM, Goldman JM, Lechler RI,
Ritter MA. IL-13 production by donor T cells is prognostic of
acute graft-versus-host disease following unrelated donor stem
cell transplantation. Blood. 2004;103:717.
0. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of
graft versus host disease by inactivation of host antigen-pre-
senting cells. Science. 1999;285:412.
1. Tazzari PL, Bolognesi A, De Totero D, et al. B-B10 (anti-
CD25)-saporin immunotoxin—a possible tool in graft-versus-
host disease treatment. Transplantation. 1992;54:351.
2. Favre A, Cerri A, Bacigalupo A, Lanino E, Berti E, Grossi CE.
Immunohistochemical study of skin lesions in acute and chronic
graft versus host disease following bone marrow transplanta-
tion. Am J Surg Pathol. 1997;21:23.
3. Ukyo N, Hori T, Yanagita S, Ishikawa T, Uchiyama T. Co-
stimulation through OX40 is crucial for induction of an allo-
reactive human T-cell response. Immunology. 2003;109:226.
4. Tittle TV, Weinberg AD, Steinkeler CN, Maziarz RT. Expres-
sion of the T-cell activation antigen, OX-40, identiﬁes alloreac-
tive T cells in acute graft-versus-host disease. Blood. 1997;89:
4652.
5. Craston R, Koh M, Mc Dermott A, Ray N, Prentice HG,
Lowdell MW. Temporal dynamics of CD69 expression on
lymphoid cells. J Immunol Methods. 1997;209:37.
6. Ho VT, Soiffer RJ. The history and future of T-cell depletion
as graft-versus-host disease prophylaxis for allogeneic hemato-
poietic stem cell transplantation. Blood. 2001;98:3192.
7. Cavazzana-Calvo M, Fromont C, Le Deist F, et al. Speciﬁc
elimination of alloreactive T cells by an anti-interleukin-2 re-
ceptor B chain-speciﬁc immunotoxin. Transplantation. 1990;
50:1.
8. Cavazzana-Calvo M, Stephan JL, Sarnacki S, et al. Attenuation
of graft-versus-host disease and graft rejection by ex vivo im-
munotoxin elimination of alloreactive T cells in an H-2 haplo-
type disparate mouse combination. Blood. 1994;83:288.
9. Mavroudis DA, Jiang YZ, Hensel N, et al. Speciﬁc depletion of
alloreactivity against haplotype mismatched related individuals
by a recombinant immunotoxin: a new approach to graft-ver-
sus-host disease prophylaxis in haploidentical bone marrow
transplantation. Bone Marrow Transplant. 1996;17:793.
0. Mavroudis DA, Dermime S, Molldrem J, et al. Speciﬁc deple-
tion of alloreactive T cells in HLA-identical siblings: a method
for separating graft-versus-host and graft-versus-leukaemia re-
actions. Br J Haematol. 1998;101:565.
1. Montagna D, Yvon E, Calcaterra V, et al. Depletion of allo-
reactive T cells by a speciﬁc anti-interleukin-2 receptor p55
chain immunotoxin does not impair in vitro antileukemia and
antiviral activity. Blood. 1999;93:3550.2. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al. Im-
82mune reconstitution without graft-versus-host disease after
haemopoietic stem-cell transplantation: a phase 1/2 study.
Lancet. 2002;360:130.
3. Solomon SR, Tran T, Carter CS, et al. Optimized clinical-scale
culture conditions for ex vivo selective depletion of host-reac-
tive donor lymphocytes: a strategy for GvHD prophylaxis in
allogeneic PBSC transplantation. Cytotherapy. 2002;4:395.
4. Amrolia PJ, Muccioli-Casadei G, Yvon E, et al. Selective de-
pletion of donor alloreactive T cells without loss of antiviral or
antileukemic responses. Blood. 2003;102:2292.
5. Koh MB, Prentice HG, Lowdell MW. Selective removal of
alloreactive cells from haematopoietic stem cell grafts: graft
engineering for GVHD prophylaxis. Bone Marrow Transplant.
1999;23:1071.
6. Koh MB, Prentice HG, Corbo M, Morgan M, Cotter FE,
Lowdell MW. Alloantigen-speciﬁc T-cell depletion in a major
histocompatibility complex fully mismatched murine model
provides effective graft-versus-host disease prophylaxis in the
presence of lymphoid engraftment. Br J Haematol. 2002;118:
108.
7. Hartwig UF, Robbers M, Wickenhauser C, Huber C. Murine
acute graft-versus-host disease can be prevented by depletion of
alloreactive T lymphocytes using activation-induced cell death.
Blood. 2002;99:3041.
8. Guimond M, Balassy A, Barrette M, Brochu S, Perreault C,
Roy DC. P-glycoprotein targeting: a unique strategy to selec-
tively eliminate immunoreactive T cells. Blood. 2002;100:375.
9. Rieser C, Bock G, Klocker H, Bartsch G, Thurnher M. Pros-
taglandin E2 and tumor necrosis factor alpha cooperate to
activate human dendritic cells: synergistic activation of inter-
leukin 12 production. J Exp Med. 1997;186:1603.
0. Smith CA, Ng CY, Heslop HE, et al. Production of genetically
modiﬁed Epstein-Barr virus-speciﬁc cytotoxic T cells for adop-
tive transfer to patients at high risk of EBV-associated lympho-
proliferative disease. J Hematother. 1995;4:73.
1. Szabolcs P, Moore MA, Young JW. Expansion of immunos-
timulatory dendritic cells among the myeloid progeny of hu-
man CD34 bone marrow precursors cultured with c-kit li-
gand, granulocyte-macrophage colony-stimulating factor, and
TNF-alpha. J Immunol. 1995;154:5851.
2. Longo-Sorbello GS, Bertino JR. Current understanding of
methotrexate pharmacology and efﬁcacy in acute leukemias.
Use of newer antifolates in clinical trials. Haematologica. 2001;
86:121.
3. vander Spek J, Cassidy D, Genbauffe F, Huynh PD, Murphy JR.
An intact transmembrane helix 9 is essential for the efﬁcient
delivery of the diphtheria toxin catalytic domain to the cytosol of
target cells. J Biol Chem. 1994;269:21455-21459.
4. Re GG, Waters C, Poisson L, Willingham MC, Sugamura K,
Frankel AE. Interleukin 2 (IL-2) receptor expression and sen-
sitivity to diphteria fusion toxin DAB389IL-2 in cultured he-
matopoietic cells. Cancer Res. 1996;56:2590-2595.
5. Valteau-Couanet D, Cavazzana-CalvoM, LeDeist F, Fromont C,
Fischer A. Functional study of residual T lymphocytes after spe-
ciﬁc elimination of alloreactive T cells by a speciﬁc anti-interleu-
kin-2 receptor Bk chain immunotoxin [corrected and republished
article originally printed in Transplantation 1993;56:737-8].
Transplantation. 1993;56:1574.
6. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of
graft versus host disease by inactivation of host antigen-pre-
senting cells. Science. 1999;285:412.
33
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
IL-2 IT and TMT Deplete Alloreactivity in Synergy
B7. Hart DN. Dendritic cells: unique leukocyte populations which
control the primary immune response. Blood. 1997;90:3245.
8. Banchereau J, Steinman RM. Dendritic cells and the control of
immunity. Nature. 1998;392:245.
9. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and
antigen presenting function of dendritic cells. Curr Opin Im-
munol. 1997;9:10.
0. Blazar BR, Sharpe AH, Taylor PA, et al. Infusion of anti-B7.1
(CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits
murine graft-versus-host disease lethality in part via direct
effects on CD4 and CD8 T cells. J Immunol. 1996;157:
3250-3259.
1. Buhlmann JE, Gonzalez M, Ginther B, et al. Cutting edge:
sustained expansion of CD8 T cells requires CD154 expres-
sion by Th cells in acute graft versus host disease. J Immunol.
1999;162:4373.
2. Blazar BR, Sharpe AH, Chen AI, et al. Ligation of OX40
(CD134) regulates graft-versus-host disease (GVHD) and graft
rejection in allogeneic bone marrow transplant recipients.
Blood. 2003;101:3741.
3. Lane PJ, Brocker T. Developmental regulation of dendritic cell
function. Curr Opin Immunol. 1999;11:308.
4. Watts TH, DeBenedette MA. T cell co-stimulatory molecules
other than CD28. Curr Opin Immunol. 1999;11:286.
5. Sun Q, Burton RL, Dai LJ, Britt WJ, Lucas KG. B lympho-
blastoid cell lines as efﬁcient APC to elicit CD8 T cell
responses against a cytomegalovirus antigen. J Immunol. 2000;
165:4105.
6. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for
EBV lymphoproliferative disease. Immunol Rev. 1997;157:217.
7. Doney KC, Storb R, Beach K, et al. A toxicity study of trime-
trexate used in combination with cyclosporine as acute graft-
B&MTversus-host disease prophylaxis in HLA-mismatched, related
donor bone marrow transplants. Transplantation. 1995;60:55.
8. Ho VT, Zahrieh D, Hochberg E, et al. Safety and efﬁcacy of
denileukin diftitox in patients with steroid-refractory acute
graft-versus-host disease after allogeneic hematopoietic stem
cell transplantation. Blood. 2004;104:1224-1226.
9. Szabolcs P, Park KD, Reese M, Marti L, Broadwater G,
Kurtzberg J. Coexistent naive phenotype and higher cycling
rate of cord blood T cells as compared to adult peripheral
blood. Exp Hematol. 2003;31:708.
0. Szabolcs P, Marti L, Reese M, Kurtzberg J, Park KD. In vitro
priming and expansion of CMV-speciﬁc TH1 and TC1 T cells
from naive cord blood lymphocytes by autologous dendritic
cells. Biol Blood Marrow Transplant. 2003 (abstr.).
1. Molldrem JJ, Lee PP, Wang C, et al. Evidence that speciﬁc T
lymphocytes may participate in the elimination of chronic my-
elogenous leukemia. Nat Med. 2000;6:1018.
2. Mutis T, Goulmy E. Hematopoietic system-speciﬁc antigens as
targets for cellular immunotherapy of hematological malignan-
cies. Semin Hematol. 2002;39:23.
3. Burrows SR, Khanna R, Burrows JM, Moss DJ. An alloresponse
in humans is dominated by cytotoxic T lymphocytes (CTL)
cross-reactive with a single Epstein-Barr virus CTL epitope:
implications for graft-versus-host disease. J Exp Med. 1994;179:
1155.
4. Sakaguchi S. Naturally arising CD4 regulatory T cells for
immunologic self-tolerance and negative control of immune
responses. Annu Rev Immunol. 2004;22:531.
5. Contassot E, Robinet E, Angonin R, et al. Differential effects of
cyclosporin A on the alloreactivity of fresh and ex vivo-ex-
panded T lymphocytes. Bone Marrow Transplant. 1998;22:1097.
783
